Legacy Medical Device Cybersecurity Risks in Hospitals

What are the cybersecurity risks of legacy medical devices in hospitals? It’s a question more hospital security teams are asking, and not finding easy answers to. Hospitals operate some of the most sophisticated care environments in the world: robotic surgery systems, real-time patient monitoring networks, AI-assisted diagnostics. And underneath all of it, many run Windows XP, long-dated firmware, and network protocols that were never designed to touch the internet.

Legacy devices can remain in service beyond vendor software support. Device life and support periods vary; compare the actual inventory with vendor support commitments rather than assuming a universal lifespan gap.

By the end of this article, you will know how to identify the specific cybersecurity risks of legacy medical devices on your clinical network, score your most exposed assets, apply immediate compensating controls, and build a realistic 90-day remediation roadmap aligned with FDA and IMDRF guidance.

Why This Matters

The security posture of hospitals is directly impacted by legacy medical devices that operate on outdated software and firmware components, creating critical vulnerabilities. These devices, designed for longevity exceeding their software support lifecycles, often run on operating systems no longer receiving security patches, exposing them to known exploits. This situation jeopardizes patient data privacy, as breaches can lead to unauthorized access to sensitive health information. More critically, compromised devices can disrupt clinical operations, impede patient care delivery, and even directly endanger patient safety through device malfunction or manipulation. The FDA's February 3, 2026 final guidance underscores that cybersecurity is patient safety. Adherence to standards like IEC 81001-5-1 and ISO 27001 is essential for managing these risks. Ignoring these vulnerabilities is not merely a compliance issue but a direct threat to the integrity of healthcare delivery.

Why Legacy Medical Devices Create Outsized Risk on Clinical Networks

Legacy devices are not simply unsupported enterprise laptops dropped into a clinical setting. They are fundamentally different, and the risk calculus is different too. You cannot take a cardiac monitor offline to run a security scan the way an IT team can reboot a server at 2 a.m. Clinical criticality and security maintenance are in direct tension, and that tension has no clean resolution in most hospital environments.

The Lifecycle Mismatch That Nobody Planned For

Clinical equipment can outlast its underlying software support. Unsupported operating systems and firmware may leave vulnerabilities without a routine vendor fix. Assess support status and known vulnerabilities device by device; no hospital-wide prevalence percentage is assumed here.

What “End of Support” Actually Means for Your Network

End-of-support does not mean the device stops working. It generally means routine vendor support has ended; exceptional fixes or extended support may still be available. Confirm the vendor policy and assess each vulnerability. Every day a device stays on your network after end-of-support, the exposure window grows. Attackers actively scan for these devices. They know exactly which CVEs apply to which unsupported platforms, and they use that knowledge.

The Workflow Cost Behind Replacement Decisions

Replacement planning must account for clinical dependencies, not just the purchase price. An imaging system may connect to a PACS, an infusion pump may depend on a drug library, and a monitor may feed alarm middleware. Changing one device can require changes to connected systems and staff workflows.

Clinical engineering, security, procurement, and care teams should identify those dependencies before setting a replacement date. Include installation downtime, configuration work, staff training, and continuity of care in the plan. A device that still performs its clinical function can nevertheless require security mitigations or replacement when software support ends.

What Risks Do Legacy Medical Devices Pose? The Specific Vulnerabilities

Once you understand the structural problem, you need to know what you are actually looking for when you audit your environment. The vulnerabilities in aging medical equipment fall into a few consistent categories, and they compound each other.

Unpatched Operating Systems and Outdated Firmware

Legacy operating systems can complicate device security maintenance. The FDA issued its Contec CMS8000 and Epsimed MN-120 safety communication on January 30, 2025. Its July 2, 2025 update describes a software patch that fully removes networking functionality, leaving local monitoring only, and recommends installation by staff with appropriate expertise. 1

Default Credentials, Insecure Protocols, and Poor Segmentation

Weak credentials, legacy protocols, and flat networks can expose devices to lateral movement. Check the actual inventory against CISA's KEV catalog; a vulnerability being listed does not prove exploitation on a particular hospital network.

What Happens When These Vulnerabilities Get Exploited

The technical vulnerabilities are real. So are the outcomes when they get exploited. The following examples distinguish disclosed vulnerabilities from observed operational harm.

Operational Disruptions Hospitals Have Reported

Device or supporting-system downtime can interrupt care, force manual workflows, and delay treatment. Assess these scenarios using local clinical dependencies rather than extrapolating industry survey percentages to every hospital.

Patient Safety Implications the Data Reveals

Beyond operational disruptions, the documented clinical risks include altered data displayed on patient monitors, inaccurate readings on implanted devices, and denial-of-service conditions that crash devices mid-use. The FDA’s 2025 alert on the Contec CMS8000 specifically cited risks of device crashes, data corruption, and unauthorized access to patient PHI. A 2022 FBI report documented vulnerabilities in unpatched insulin pumps, pacemakers, and defibrillators with potential for inaccurate readings and health endangerment. Regulators, including the FDA, IMDRF, and the FBI, treat these as patient safety risks, not just IT incidents, even where specific documented patient-harm cases remain limited in public reporting. That framing matters when you are making the case for resource allocation and board-level attention.

How to Identify and Rank Your Highest-Risk Assets

You cannot fix what you cannot see. Most hospitals are working from incomplete, outdated, or siloed asset inventories. That is the first problem to solve, and it has to be solved before any controls are worth deploying.

Starting with a Complete Clinical Device Inventory

A useful asset inventory captures device type, manufacturer, OS and firmware version, network connectivity, end-of-support date, and clinical criticality. Automated network discovery tools purpose-built for healthcare environments close gaps that manual methods miss. Claroty’s research suggests a meaningful share of hospital devices go untracked at any given time, a gap that makes compensating controls difficult to deploy consistently. Clinical engineering and IT security need to own this inventory together. When those teams operate in silos, visibility breaks down at exactly the seam between biomedical management and network security, which is precisely where attackers look for gaps. Practical guidance on why and how to inventory medical devices for confident cybersecurity can help operationalize discovery efforts, and our analysis of the Two Medical Device Cybersecurity Gaps: Dispersed Responsibility and a Scarcity of Asset Inventory, Blue Goat Cyber explains the organizational friction that typically undermines those programs.

A Scoring Approach That Cuts Through the Noise

Once your inventory exists, prioritization needs a clear framework rather than gut instinct or vendor pressure. Score each device on three dimensions: known exploitability (is there a public CVE or active KEV?), network exposure (is the device internet-accessible or on a flat network?), and clinical criticality (what happens to patient care if this device goes down?). Devices that score high on all three get attention first, regardless of replacement cost or vendor relationship. A mid-tier imaging system running an unsupported OS on a flat network with a public CVE ranks ahead of a newer device with no known vulnerabilities. The score drives the priority, not the price tag.

Compensating Controls That Reduce Exposure Without Replacing Devices

Most hospitals cannot replace legacy devices on short notice. Budget cycles, clinical dependencies, and procurement timelines make immediate replacement unrealistic. Compensating controls are the practical middle ground, and they work when implemented with discipline and layering.

Network Segmentation and Isolation

Segmentation can be an important compensating control for legacy device risk. Isolating clinical devices in dedicated VLANs, blocking unnecessary outbound traffic, and applying micro-segmentation for the highest-risk assets directly limits an attacker’s ability to move laterally from an initial entry point to critical equipment. Virtual segmentation approaches are less disruptive than physical network redesigns and can be deployed in weeks rather than months. Both FDA guidance and the IMDRF N70 legacy-device guidance explicitly endorse network segmentation as a primary compensating control for devices that cannot be patched, making this approach well-documented for regulatory purposes.

Virtual Patching, Monitoring, and Access Controls

See also: PATCH Act: Legacy Device Cyber Gaps, Medical Device Cybersecurity Lifecycle, and Total Product Lifecycle Security for Devices.

Virtual patching through intrusion prevention or protocol filtering can block specific exploit paths without changing device software. A web application firewall is relevant only where the exposed service and traffic are supported. Confirm that filtering preserves clinically necessary communications before deployment.

Passive monitoring can identify changes in clinical device traffic without active scanning. Access controls, credential rotation where the device supports it, and removal of unnecessary remote access address additional exposure. No single control is sufficient; document what each layer covers and what remains exposed.

How to Decide When a Legacy Device Needs Replacement

Replacement decisions should depend on device-specific residual risk and clinical dependencies, not age alone. Segmentation and filtering reduce exposure but do not remove an underlying software vulnerability. Review whether those controls still cover the exploit path as threats, connectivity, and clinical use change.

Prioritize replacement review when an unpatchable weakness has a credible exploit path, the device performs a safety-critical function, or necessary connectivity prevents effective isolation. Compare the recurring work of monitoring and maintaining controls with the clinical and operational costs of migration. These factors prompt review; they are not an automatic rule that every unsupported device must be removed immediately.

Record the mitigation owner, remaining exposure, review triggers, vendor support status, and a replacement milestone where replacement is selected. Coordinate funding and transition arrangements with procurement and clinical engineering. Reassess after a new vulnerability, a failed control, or a change in clinical use rather than assuming a compensating control remains effective indefinitely.

What Manufacturers Should Communicate About Legacy Device Support

Hospitals need clear support information from manufacturers to manage aging device fleets. Request the supported software and firmware versions, end-of-support dates, available patches, vulnerability advisories, disclosure contact, and any limits on proposed mitigations. Manufacturer guidance should identify which communications a device needs and which isolation measures could disrupt clinical operation.

The FDA's Postmarket Management of Cybersecurity in Medical Devices guidance recommends lifecycle vulnerability monitoring, coordinated disclosure, and risk-based remediation. Guidance recommendations are not themselves binding legal duties. Correction and removal reporting under 21 CFR Part 806 is a separate legal question that depends on the action and applicable criteria.

The FDA's February 3, 2026 guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, addresses manufacturer quality management and premarket evidence. It does not retroactively require a new SBOM submission for every fielded legacy device. For the manufacturer-side distinction, see Legacy Medical Device Cybersecurity: The 2026 FDA Guide.

A 90-Day Roadmap Aligned with FDA and IMDRF Guidance

Neither the FDA nor IMDRF mandates immediate replacement of legacy devices. What they do expect is documented risk assessments, active compensating controls, transparent communication with device manufacturers, and ongoing monitoring. The IMDRF N70 framework establishes clear roles for both manufacturers and healthcare delivery organizations at each lifecycle stage, including post-end-of-support. Hospitals operating legacy devices are expected to demonstrate active risk management, not passive tolerance.

Steps to Execute in the Next 90 Days

Structure your response in three phases. In days one through 30, begin automated discovery of your clinical asset inventory and prioritize identification of every device carrying an active KEV from CISA’s catalog, recognizing that a complete picture may develop iteratively as discovery tools surface previously untracked assets. In days 31 through 60, implement network segmentation for your highest-risk assets, enable passive monitoring on clinical network segments, and formally document initial compensating controls. In days 61 through 90, initiate direct manufacturer conversations about risk-sharing and available mitigations, identify devices for replacement prioritization based on your scoring model, and finalize your compensating control documentation in a format that supports both internal review and regulatory interaction.

Blue Goat Cyber works directly with device makers on legacy security remediation and postmarket compliance programs. That manufacturer-side experience can accelerate conversations considerably, particularly when a hospital needs technical documentation or risk-sharing agreements that manufacturers are not proactively providing. For practical guidance on how manufacturers can support operational cybersecurity, see How Can Medical Device Manufacturers Support Operational Cybersecurity?, Blue Goat Cyber.

The Cybersecurity Risks of Legacy Medical Devices Are on Your Network Today

The cybersecurity risks of legacy medical devices in hospitals are not abstract. They are on your network right now, carrying known vulnerabilities, and in many cases lacking any path to a vendor-supplied fix. That is the reality most hospital security teams are managing, even if the full scope is not yet visible in their asset data.

The path forward does not require a full replacement budget or a multi-year transformation. It requires honest visibility, disciplined prioritization, layered compensating controls, and a documented plan that regulators and auditors can evaluate. Virtual segmentation and virtual patching can be deployed in weeks. Full remediation and procurement timelines run longer, but meaningful progress is achievable in 90 days with the right focus.

If your hospital needs to engage device manufacturers on legacy security posture or postmarket compliance, Blue Goat Cyber can help. The work sits at the intersection of FDA cybersecurity requirements and real-world device security, exactly where these conversations need to happen.

Need help? Our team supports manufacturers with FDA cybersecurity submissions end-to-end. Explore our medical device cybersecurity services or book a discovery call.

How Blue Goat Cyber Approaches This

Blue Goat Cyber addresses legacy medical device cybersecurity by focusing on pragmatic risk reduction and compliance. Our approach begins with a thorough asset inventory and vulnerability assessment, identifying critical exposures. We employ threat modeling to understand potential attack vectors unique to older systems and develop targeted compensating controls. Unlike general cybersecurity firms, our team has direct experience with medical device ecosystems, including clinicians, former military red team operators (OSCP & CISSP certified), and regulatory experts. We specialize in developing and implementing risk mitigation strategies that extend the secure operational life of devices without requiring immediate replacement. We work directly with manufacturers on postmarket security programs, often identifying vulnerabilities long before they impact hospitals. Our services, including penetration testing and risk assessments, are tailored to meet FDA requirements. We excel in generating actionable remediation roadmaps that align with current regulatory expectations. If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed. Learn more about our postmarket services at: /services/fda-postmarket-cybersecurity-services.

After clearance, our postmarket cybersecurity services cover vulnerability monitoring, patch planning, and incident response for devices in the field.

Related reading: Windows LAPS for Medical Devices: Manage Local Admin Passwords Safely (Not GPP), IEC 80001-1: Hospital Network Risk Management Explained.

Frequently Asked Questions

What makes legacy medical devices risky?

Legacy medical devices become risky when their vendor software support ends, leaving them without security updates for critical vulnerabilities. This gap allows attackers to exploit known weaknesses, potentially compromising patient care and data.

How does the FDA view legacy medical device risks?

The FDA treats medical device cybersecurity as a patient safety concern. Its postmarket guidance recommends lifecycle vulnerability management and risk-based remediation by manufacturers. Its February 3, 2026 premarket guidance addresses manufacturer quality management and submission evidence. Neither guidance means every older device in a hospital automatically needs a new premarket submission. Hospitals should request device-specific support information and coordinate mitigations with the manufacturer.

Can unsupported devices remain on a clinical network?

Yes, but with significant caveats. If an unsupported device cannot be replaced, hospitals must implement strong compensating controls like network segmentation, virtual patching, and enhanced monitoring to reduce its exposure to threats.

What are common vulnerabilities in legacy devices?

Common vulnerabilities include unpatched operating systems, outdated firmware, default or weak credentials, and insecure communication protocols. These issues provide attackers with multiple entry points into clinical networks.

How can hospitals identify their riskiest devices?

Hospitals should conduct a complete clinical device inventory. Then, score each device based on known exploitability, network exposure, and clinical criticality to prioritize remediation efforts effectively.

When should hospitals replace a legacy medical device?

Hospitals should review replacement when device-specific residual risk cannot be sufficiently reduced by available mitigations. Consider exploit paths, clinical criticality, required connectivity, vendor support, and the continuing cost of compensating controls. Unsupported software alone is not a universal replacement deadline. Plan the transition with clinical engineering and care teams so security changes do not interrupt necessary care.

Related: The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks

CTA

If a legacy device in your fleet needs manufacturer support, gather its software versions, support notices, known vulnerabilities, and clinical dependencies. Use Legacy Medical Device Cybersecurity: The 2026 FDA Guide to frame questions about available mitigations, support limits, and postmarket documentation before agreeing a transition plan.